Applications are now open for the Children’s Tumor Foundation‘s (CTF) 2021 cycle of Drug Discovery Initiative Registered Reports (DDIRR) award program, a program to fund early stage testing of candidate drug therapies for neurofibromatosis treatment. This program is guided by the Registered Reports model, which involves pre-results peer review to align on scientific values and practices and encourages rigorous and reproducible science.

To facilitate this model, CTF and the publisher PLOS ONE have partnered together.¬†DDIRR’s first output article, titled “Evaluating modified diets and dietary supplement therapies for reducing muscle lipid accumulation and improving muscle function in neurofibromatosis type 1 (NF1)”, was just published PLOS ONE in August 2020.

Letters of intent to apply for DDIRR are due December 14, 2020.

DDIRR Application
DDIRR Announcement from CTF